Actavis has 18 principal global R&D facilities focused on identifying and pursuing global product development opportunities across all three of its core product businesses.

Our R&D activities focus on products using solid dosage form, oral-controlled and sustained release, semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies and the application of these technologies to proprietary drug forms.